Table 2 Baseline characteristics associated with SVR12 to triple therapy
Baseline characteristics | All patients (n = 105) | Patients who achieved SVR12 to triple therapy (n = 69) | Patients who did not achieve SVR12 to triple therapy (n = 36) | P value |
|---|---|---|---|---|
Gender, female (n, %) | 31 (29.5) | 25 (36.2) | 6 (16.6) | 0.037 |
Age, years (median, IQR) | 52 (10) | 52 (16) | 53 (8) | 0.151 |
Age, <52 years (n, %) | 46 (43.8) | 33 (47.8) | 13 (36.1) | 0.251 |
Ethnicity | ||||
White/Caucasian (n, %) | 86 (81.9) | 58 (84.1) | 28 (77.8) | 0.550 |
Black (n, %) | 6 (5.7) | 2 (2.9) | 4 (11.1) | 0.085 |
Other (n, %) | 13 (12.3) | 9 (13) | 4 (11.1) | 0.775 |
Liver fibrosis | ||||
Non-advanced, i.e. METAVIR F0-F2 (n, %) | 55 (52.4) | 41 (59.4) | 14 (38.9) | 0.046 |
Advanced, i.e. METAVIR F3 or F4 (n, %) | 50 (47.6) | 28 (40.6) | 22 (61.1) | |
Previous HCV treatment | ||||
Naïve | 29 (27.6) | 22 (31.9) | 7 (19.4) | 0.340 |
Interruption due to side effects | 5 (4.8) | 3 (4.3) | 4 (11.1) | 0.783 |
Viral breakthrough | 7 (6.7) | 3 (4.3) | 4 (11.1) | 0.393 |
Relapser | 33 (31.4) | 28 (40.6) | 5 (13.9) | 0.020 |
Partial responder | 8 (7.6) | 4 (5.8) | 4 (11.1) | 0.587 |
Null responder | 23 (21.9) | 9 (13) | 14 (38.9) | 0.008 |
Naïve, interruption due to side effects, viral breakthrough and relapsers (n, %) | 74 (70.5) | 56 (81.2) | 18 (50.0) | 0.001 |
Partial and null responders (n, %) | 31 (29.5) | 13 (18.8) | 18 (50.0) | |
HCV protease inhibitor | ||||
Boceprevir (n, %) | 17 (16.2) | 13 (18.8) | 4 (11.1) | 0.307 |
Telaprevir (n, %) | 88 (83.8) | 56 (81.2) | 32 (88.9) | |
HCV genotype | ||||
1a | 45 (42.9) | 21 (30.4) | 24 (66.7) | 0.001 |
1b | 43 (40.9) | 35 (50.7) | 8 (22.2) | |
1 non-subtyped | 17 (16.2) | 13 (18.8) | 4 (11.1) | 0.307 |
1a and 1 non-subtyped (n, %) | 62 (59.1) | 34 (49.3) | 28 (77.8) | 0.005 |
1b (n, %) | 43 (40.9) | 35 (50.7) | 8 (22.2) | |
HCV viral load, IU/mL (median, IQR) | 1,833,451 (3,459,687) | 1,417,630 (2,505,928) | 2,115,100 (4,038,313) | 0.005 |
HCV viral load, <800,000 IU/mL (n, %) | 30 (28.5) | 25 (36.2) | 5 (13.9) | 0.016 |
IL28B rs12979860 genotype | ||||
CC (n, %) | 23 (21.9) | 20 (29) | 3 (8.3) | 0.015 |
CT (n, %) | 67 (63.8) | 42 (60.9) | 25 (69.4) | 0.385 |
TT (n, %) | 15 (14.3) | 7 (10.1) | 8 (22.2) | 0.093 |
IL28B rs8099917 genotype | ||||
TT (n, %) | 45 (42.8) | 34 (49.3) | 11 (30.5) | 0.066 |
GT (n, %) | 51 (48.6) | 31 (44.9) | 20 (55.6) | 0.301 |
GG (n, %) | 9 (8.6) | 4 (5.8) | 5 (13.9) | 0.160 |
Combinations of IL28B SNPs | ||||
rs12979860-CC and rs8099917-TT (n, %) | 23 (21.9) | 20 (29) | 3 (8.3) | 0.015 |
rs12979860-CC and rs8099917-GT (n, %) | 0 | 0 | 0 | / |
rs12979860-CC and rs8099917-GG (n, %) | 0 | 0 | 0 | / |
rs12979860-CT and rs8099917-TT (n, %) | 22 (20.9) | 14 (20.3) | 8 (22.2) | 0.514 |
rs12979860-CT and rs8099917-GT (n, %) | 45 (42.9) | 28 (40.6) | 17 (47.2) | 0.817 |
rs12979860-CT and rs8099917-GG (n, %) | 0 | 0 | 0 | / |
rs12979860-TT and rs8099917-TT (n, %) | 0 | 0 | 0 | / |
rs12979860-TT and rs8099917-GT (n, %) | 6 (5.7) | 3 (4.3) | 3 (8.3) | 0.404 |
rs12979860-TT and rs8099917-GG (n, %) | 9 (8.6) | 4 (5.8) | 5 (13.9) | 0.160 |